---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-049822"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2026-07-27T20:31:46+00:00"
generated_at: "2026-07-27T20:33:09.927695+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology reports record annual revenue of $59.4M; FY2026 operating loss of $1.1M vs prior year income of $4.6M

## Summary
- Record annual revenue $59.4M, up 4% YoY; Q4 revenue $13.8M, up 12% YoY.
- FY2026 operating loss $1.1M (incl. $1.2M stock comp, $1.4M D&A) vs prior year operating income $4.6M.
- Adjusted EBITDA $1.6M for FY2026, down from $7.1M prior year; Q4 adjusted EBITDA $158K positive.
- Oncology services margin 48% for FY2026 vs 50% prior year; Q4 margin improved to 51% from 41%.
- Cash $4.9M, no debt; continued investment in radiopharmaceuticals, data platform, commercial organization.

## SEC filing metadata
- accession: 0001628280-26-049822
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2026-07-27T20:31:46+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000162828026049822/0001628280-26-049822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000162828026049822/csbr-20260727.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-049822
- JSON: https://secwatch.observer/filing/0001628280-26-049822.json
- Plain text: https://secwatch.observer/filing/0001628280-26-049822.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.